(Q29615841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Hepatocellular carcinoma (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Jordi Bruix

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Andrew Kenneth Burroughs

series ordinal

2

object named as

Andrew Burroughs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

21 December 2019

language of work or name

1 reference

30 April 2017

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

362

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

9399

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

1907-1917

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

Estimating the world cancer burden: Globocan 2000.

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Trends in primary liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Epidemiology of primary liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Genetics of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

The challenge of developing a vaccine against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Subclinical hepatocellular carcinoma: An analysis of 391 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgica

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Simplified staging for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatocellular carcinoma: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Power Doppler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

An analysis of 412 cases of hepatocellular carcinoma at a Western center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Preoperative predictors of survival after resection of small hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatic resection versus transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatobiliary surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Surgery for small liver cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

A model to predict survival in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

The new liver allocation system: moving toward evidence-based transplantation policy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Model for end-stage liver disease (MELD) and allocation of donor livers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Influence of Preoperative Transarterial Lipiodol Chemoembolization on Resection and Transplantation for Hepatocellular Carcinoma in Patients With Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Adult-to-adult transplantation of the right hepatic lobe from a living donor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Transplantation of liver grafts from living donors into adults--too much, too soon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Local ablation therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Complications of radiofrequency coagulation of liver tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Tamoxifen Does Not Improve Survival of Patients With Advanced Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Sex hormone receptors in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914964-1

7 January 2021

10.1016/S0140-6736(03)14964-1

Identifiers

DOI

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

30 April 2017

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14667750%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14667750

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017